Company / R&D Expense
Praxis Precision Medicines, Inc. R&D Expense History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$267.1M
FY2025
5-year range
$86.8M / $267.1M
FY2021-FY2025
Trend
+75.3%
vs FY2024
Sector context
#68 of 210
Health Care
What the data says
At $267M, Praxis Precision Medicines, Inc.'s r&d expense ranks #68 of 210 in the Health Care sector. Improved from $87M to $267M over the past 2 years.
Based on SEC 10-K filings.
$267M in FY2025 with a 5-year CAGR of +42.8%.
Improved from $87M to $267M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +19.9%
- 5-Year CAGR
- +42.8%
- 10-Year CAGR
- -
Sector benchmark
#68 of 210 in Health CareTop 32% of 210This company $267.1M Sector average $644.1M
▼
-58.5% below sector average
Key checks
Key Insights
- 5-year CAGR of +42.8%, indicating consistent growth.
- In FY2025, r&d expense increased 75.3% year-over-year.
- Ranks #68 out of 210 companies in the Health Care sector.
- Lowest r&d expense in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 4.48 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $267.1M | +75.3% |
| FY2024 | $152.4M | +75.7% |
| FY2023 | $86.8M | -44.0% |
| FY2022 | $155.0M | +28.9% |
| FY2021 | $120.3M | +167.4% |
| FY2020 | $45.0M | +52.2% |
| FY2019 | $29.6M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026